Active Ingredients:-
Cholesterol and Phospholipid based bilayer liposomes; QS-21/3D-MPLA each at 100 µg/ml.
Product Applications:-
Herpes zoster vaccine / Neurodegenerative disease vaccine, etc.
Quality level:-
Research grade / GMP grade
Liposome Di-adjuvant B is a liposome-based combination vaccine adjuvant system designed to enhance and modulate immune responses to vaccine antigens. It uses lipid-based vesicles to present or deliver immunostimulatory components in a controlled manner.
The exact composition of products sold under the commercial name “Liposome Di-adjuvant B” can vary by manufacturer, so it is important not to assign a CAS number, molecular formula, or molecular weight without the supplier's specification.
A liposome is a microscopic vesicle formed from one or more phospholipid bilayers. It can:
- Encapsulate or associate with vaccine antigens
- Carry immunostimulatory molecules
- Improve antigen presentation
- Promote uptake by antigen-presenting cells
- Help control the release and localization of an antigen/adjuvant
A di-adjuvant generally refers to a formulation containing two complementary adjuvant components or two immune-stimulating mechanisms.
2. How Liposome Di-Adjuvant B works
A simplified mechanism is:
Antigen + Liposome Di-Adjuvant B → uptake by immune cells → enhanced antigen presentation → activation of innate immunity → stronger adaptive immune response
The liposomal system can help bring antigen and immunostimulatory components into proximity with dendritic cells and macrophages, potentially improving the resulting immune response.
3. Typical characteristics
ParameterDescriptionProduct typeLiposome-based combination adjuvantFormUsually aqueous dispersion/suspensionCore technologyPhospholipid/lipid vesicle systemFunctionVaccine immune-response enhancementMechanismAntigen delivery + innate immune stimulationTarget cellsMainly antigen-presenting cellsResearch areaVaccine development & immunologyApplicationsPreclinical vaccine research, antigen-delivery studiesCompositionManufacturer/formulation dependentCAS No.Not applicable as a single defined substance if it is a formulationMolecular weightNot applicable to the complete formulation
4. Why use a dual-adjuvant system?
Different immune pathways can produce complementary effects. A dual-adjuvant formulation may be designed to provide:
Component 1 → innate immune activation
Component 2 → additional immune modulation
Liposome → delivery/presentation platform
This can potentially produce a more effective and appropriately directed immune response than an antigen alone.
5. Potential research applications
Liposome Di-Adjuvant B may be investigated for:
- Prophylactic vaccine development
- Recombinant-protein vaccines
- Subunit vaccine research
- Peptide antigen studies
- Therapeutic vaccine research
- Antigen-delivery studies
- Dendritic-cell activation research
- Immunogenicity studies
- Preclinical vaccine formulation development
Liposome Di-Adjuvant B
Liposome Di Adjuvant B
Liposomal Di-Adjuvant B
Liposome based adjuvant
Liposomal vaccine adjuvant
Liposome vaccine adjuvant
Liposome immunological adjuvant
Liposome adjuvant formulation
Liposome-based vaccine adjuvant
Dual adjuvant liposome
Di-adjuvant formulation
Combination vaccine adjuvant
Advanced vaccine adjuvant
Research grade liposome adjuvant
Vaccine adjuvant supplier
Vaccine adjuvant manufacturer
Vaccine adjuvant exporter
Vaccine formulation adjuvant
Liposomal antigen delivery
Liposome antigen delivery system
Vaccine antigen delivery
Antigen presentation
Antigen presenting cells
Dendritic cell activation
Macrophage activation
Innate immune stimulation
Adaptive immune response
Immunogenicity enhancement
Vaccine immunology research
Subunit vaccine adjuvant
Recombinant protein vaccine adjuvant
Peptide vaccine adjuvant
Therapeutic vaccine adjuvant
Preclinical vaccine research
Vaccine formulation research
Nanoparticle vaccine adjuvant
Lipid nanoparticle adjuvant
Immunostimulatory liposome
- Buy Liposome Di-Adjuvant B
- Liposome Di-Adjuvant B supplier
- Liposome Di-Adjuvant B manufacturer
- Liposome Di-Adjuvant B exporter
- Liposome Di-Adjuvant B distributor
- Liposome adjuvant wholesale
- Liposome vaccine adjuvant supplier
- Vaccine adjuvant bulk supplier
- Vaccine research reagent supplier
- Vaccine development raw materials
- Immunology research products supplier
- Pharmaceutical research chemicals supplier
- Biotech research reagent supplier
- Custom liposome formulation
- Bulk liposome adjuvant
- International vaccine adjuvant supplier
- Liposome Di-Adjuvant B USA
- Liposome vaccine adjuvant supplier USA
- Vaccine adjuvant supplier USA
- Liposomal adjuvant manufacturer USA
- Vaccine research reagent supplier USA
- Immunology research products USA
Liposome Di-Adjuvant B Canada
Liposome vaccine adjuvant supplier Canada
Vaccine adjuvant supplier Canada
Vaccine research reagent Canada
Liposome Di-Adjuvant B UK
Liposomal vaccine adjuvant supplier UK
Vaccine adjuvant supplier UK
Vaccine research products UK
Immunology reagent supplier UK
Liposome Di-Adjuvant B Germany
Liposome vaccine adjuvant supplier Germany
Vaccine adjuvant supplier Germany
Vaccine research reagent Germany
Liposome Di-Adjuvant B France
Liposomal vaccine adjuvant supplier France
Vaccine adjuvant supplier France
Liposome Di-Adjuvant B Switzerland
Vaccine adjuvant supplier Switzerland
Liposomal vaccine research Switzerland
Liposome Di-Adjuvant B Netherlands
Liposome vaccine adjuvant supplier Netherlands
Vaccine research reagent Netherlands
Liposome Di-Adjuvant B Belgium
Vaccine adjuvant supplier Belgium
Vaccine research reagent Belgium
Liposome Di-Adjuvant B India
Liposome vaccine adjuvant supplier India
Vaccine adjuvant manufacturer India
Vaccine research products India
Immunology research reagent India
Pharmaceutical research supplier India
Keywords
